Glueball Masses from Hamiltonian Lattice QCD

We calculate the masses of the $0^{++}$, $0^{--}$ and $1^{+-}$ glueballs from QCD in 3+1 dimensions using an eigenvalue equation method for Hamiltonian lattice QCD developed and described elsewhere by the authors. The mass ratios become approximately constants in the coupling region $6/g^2 \in [6.0,6.4]$, from which we estimate $M(0^{--})/M(0^{++})=2.44 \pm 0.05 \pm 0.20$ and $M(1^{+-})/M(0^{++})=1.91 \pm 0.05 \pm 0.12$.Comment: 12 pages, Latex, figures to be sent upon reques

Genomewide association study of leprosy.

BACKGROUND: The narrow host range of Mycobacterium leprae and the fact that it is refractory to growth in culture has limited research on and the biologic understanding of leprosy. Host genetic factors are thought to influence susceptibility to infection as well as disease progression. METHODS: We performed a two-stage genomewide association study by genotyping 706 patients and 1225 controls using the Human610-Quad BeadChip (Illumina). We then tested three independent replication sets for an association between the presence of leprosy and 93 single-nucleotide polymorphisms (SNPs) that were most strongly associated with the disease in the genomewide association study. Together, these replication sets comprised 3254 patients and 5955 controls. We also carried out tests of heterogeneity of the associations (or lack thereof) between these 93 SNPs and disease, stratified according to clinical subtype (multibacillary vs. paucibacillary). RESULTS: We observed a significant association (P<1.00x10(-10)) between SNPs in the genes CCDC122, C13orf31, NOD2, TNFSF15, HLA-DR, and RIPK2 and a trend toward an association (P=5.10x10(-5)) with a SNP in LRRK2. The associations between the SNPs in C13orf31, LRRK2, NOD2, and RIPK2 and multibacillary leprosy were stronger than the associations between these SNPs and paucibacillary leprosy. CONCLUSIONS: Variants of genes in the NOD2-mediated signaling pathway (which regulates the innate immune response) are associated with susceptibility to infection with M. leprae

Antiaging Effect of Pine Pollen in Human Diploid Fibroblasts and in a Mouse Model Induced by D-Galactose

The present paper was designed to investigate the effect of pine pollen against aging in human diploid fibroblast 2BS cells and in an accelerated aging model, which was established by subcutaneous injections with D-galactose daily for 8 weeks in C57BL/6J mice. Pine pollen (1 mg/mL and 2 mg/mL) is proved to delay the replicative senescence of 2BS cells as evidenced by enhanced cell proliferation, decreased SA-β-Gal activity, and reversed expression of senescence-associated molecular markers, such as p53, p21Waf1, p16INK4a, PTEN, and p27Kip1 in late PD cells. Besides, pine pollen reversed D-galactose-induced aging effects in neural activity and inflammatory cytokine levels, as indicated by improved memory latency time and reduced error rate in step-down test and decreased concentrations of IL-6 and TNF-α in model mice. Similar to the role of AGEs (advanced glycation endproducts) formation inhibitor aminoguanidine (AG), pine pollen inhibited D-galactose-induced increment of AGEs levels thus reversed the aging phenotypes in model mice. Furthermore, the declined antioxidant activity was obviously reversed upon pine pollen treatment, which may account for its inhibitory effect on nonenzymatic glycation (NEG) in vivo. Our finding presents pine pollen as an attractive agent with potential to retard aging and attenuate age-related diseases in humans

Botulinum toxin type A in treating early-stage patients with small-angle acute acquired comitant esotropia

AIM: To investigate botulinum toxin A (BTXA) efficacy on small-angle (≤25Δ) acute acquired concomitant esotropia (AACE) in early-stage patients. METHODS: The electronic medical record data of AACE patients during March 2019 and June 2023 were collected in this retrospective and hospital-based cohort study. A total of 72 small-angle AACE patients received BTXA extraocular muscle injection. Patients were grouped by onset-to-treatment time (Group A: ≤6mo, Group B: >6mo). Deviation of esotropia, eye alignment and stereopsis were analyzed at the period of pre/post-injection (1wk, 1, 3, and 6mo). Orthophoria rate at 6mo (horizontal deviation 0.05) between two groups except onset-to-treatment time (2mo vs 11mo, P0.05); while in 3 and 6mo Group A was significantly smaller than group B (all P6mo) may reduce BTXA efficacy. Early BTXA intervention benefits long-term eye alignment and stereopsis recovery

Petrogenesis of Paleozoic–Early Mesozoic Granites and Pegmatites in the Yuechengling Pluton of South China

AbstractAlthough pegmatites are volumetrically minor in the upper continental crust, these rocks host abundant rare metal deposits (e.g., Li, Be, Rb, Ta, and Nb). Pegmatites can be formed either by extensive fractional crystallization of granitic magmas or by low-degree partial melting of metasedimentary rocks. The Mao’ershan–Yuechengling composite batholith in the Nanling Range in the South China Block (SCB) is of early Paleozoic–Triassic age (440–381 and 236–204 Ma, respectively). Recently, hundreds of pegmatites associated with Nb, Ta, Be, Rb, and Li mineralization have been identified in this batholith. These pegmatites are hosted by granitic wall rocks. However, the relationships between the pegmatites and granitic wall rocks are not well constrained. To address this, we investigated the Mao’antang (MAT) and Tongzuo (TZ) pegmatites and their biotite granite wall rocks in the middle part of the Yuechengling pluton. Laser ablation inductively coupled plasma mass spectrometry zircon U–Pb ages revealed that the MAT pegmatites formed during the Permian (269 Ma) and Triassic (231 Ma) and that the MAT biotite granite wall rock records two stages of magmatic activity (271 and 231 Ma) that are coeval with the pegmatites. The TZ pegmatites probably formed during the Triassic (235 Ma), and the TZ biotite granite wall rock formed during the Silurian (435 Ma). The MAT biotite granite and pegmatites (εNdt=−12.0 to −10.6; εHft=−8.0 to −1.0), TZ pegmatites (εNdt=−10.4 to −6.1), and TZ biotite granites (εNdt=−9.1 to −8.7; εHft=−7.7 to −4.1) have enriched whole-rock Nd and zircon Hf isotopic compositions that are similar to those of early Paleozoic and Triassic S-type granites in the SCB. In addition, the whole-rock Pb isotopic compositions of the MAT and TZ pegmatites and granites are distributed along the upper crust evolution line. We suggest that the MAT and TZ biotite granites were mainly derived from Paleoproterozoic metasedimentary rocks in the middle crust. The MAT pegmatites are fractional crystallization products of the MAT biotite granites, whereas the TZ pegmatites were formed by fractional crystallization of hidden parental S-type granites. We propose that the MAT and TZ pegmatites have potential for rare metal (Nb, Ta, Be, and Li) mineralization, as they record high degrees of fractional crystallization. The MAT and TZ areas in the middle of the Yuechengling pluton are promising targets for rare metal exploration

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

DICCCOL: Dense Individualized and Common Connectivity-Based Cortical Landmarks

Is there a common structural and functional cortical architecture that can be quantitatively encoded and precisely reproduced across individuals and populations? This question is still largely unanswered due to the vast complexity, variability, and nonlinearity of the cerebral cortex. Here, we hypothesize that the common cortical architecture can be effectively represented by group-wise consistent structural fiber connections and take a novel data-driven approach to explore the cortical architecture. We report a dense and consistent map of 358 cortical landmarks, named Dense Individualized and Common Connectivity–based Cortical Landmarks (DICCCOLs). Each DICCCOL is defined by group-wise consistent white-matter fiber connection patterns derived from diffusion tensor imaging (DTI) data. Our results have shown that these 358 landmarks are remarkably reproducible over more than one hundred human brains and possess accurate intrinsically established structural and functional cross-subject correspondences validated by large-scale functional magnetic resonance imaging data. In particular, these 358 cortical landmarks can be accurately and efficiently predicted in a new single brain with DTI data. Thus, this set of 358 DICCCOL landmarks comprehensively encodes the common structural and functional cortical architectures, providing opportunities for many applications in brain science including mapping human brain connectomes, as demonstrated in this work

Addressing challenges in pediatric thrombosis: a comprehensive guideline development

BackgroundPediatric thrombosis is a relatively rare but severe condition in the field of pediatrics, with far-reaching consequences. Recent studies have indicated a rising incidence of this disease in children over the years. Additionally, the pharmacological treatment of thrombotic diseases in children faces numerous challenges. Due to significant physiological differences between children and adults, guidelines for the prevention and treatment of thrombotic diseases in adults cannot be directly applied to pediatric patients.PurposeA systematic review of the existing evidence-based medical literature should be conducted to propose pharmacological prevention and treatment recommendations for pediatric thrombotic diseases. Developing a comprehensive and practical pharmacotherapy guideline for the prevention and treatment of pediatric thrombotic diseases is essential to enhancing the rational use of medications in managing these conditions in children.MethodsThe guideline development followed the World Health Organization's (WHO) Handbook for Guideline Development. This involves systematically searching and extensively collecting data on common medication issues in the prevention and treatment of pediatric thrombosis nationwide. The Delphi method was used to survey experts and identify the clinical issues to be included. Subsequently, a systematic literature review was conducted to evaluate existing primary studies, systematic reviews, and guidelines or consensus statements from professional organizations. The quality of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. The Delphi method was employed again to reach a consensus on the recommendations and evidence levels. This process was culminated in the development of the Guideline for Pharmacological Management of Thrombotic Diseases in Children.ResultsDuring the guideline development process, a total of 29 clinical issues were collected and evaluated by 78 experts in clinical pharmacy and clinical medicine. Through two rounds of surveys, 13 clinical issues were selected. Under the supervision of two methodologists, 13 clinical pharmacotherapy recommendations were formulated.ConclusionBy conducting a comprehensive assessment of the feasibility and safety of clinical practices, the guideline provides specific anticoagulant medication recommendations for pediatric healthcare professionals. This will help enhance the prevention and treatment of pediatric thrombosis, promoting more standardized and effective medical practices